Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial
Background: Aboriginal and Torres Strait Islander peoples are disproportionately impacted by type 2 diabetes. Continuous glucose monitoring (CGM) technology (such as Abbott Freestyle Libre 2, previously referred to as Flash Glucose Monitoring) offers real-time glucose monitoring that is convenient a...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2024
|
| _version_ | 1811140295303102464 |
|---|---|
| author | Hachem, M Hearn, T Kelly, R Eer, A Moore, B Sommerville, C Atkinson-Briggs, S Twigg, S Freund, M O’Neal, D Story, D Brown, A McLean, A Sinha, A Furler, J O’Brien, R Tran Duy, A Clarke, P Braat, S Koye, DN Eades, S Burchill, L Ekinci, E |
| author_facet | Hachem, M Hearn, T Kelly, R Eer, A Moore, B Sommerville, C Atkinson-Briggs, S Twigg, S Freund, M O’Neal, D Story, D Brown, A McLean, A Sinha, A Furler, J O’Brien, R Tran Duy, A Clarke, P Braat, S Koye, DN Eades, S Burchill, L Ekinci, E |
| author_sort | Hachem, M |
| collection | OXFORD |
| description | Background: Aboriginal and Torres Strait Islander peoples are disproportionately impacted by type 2 diabetes. Continuous glucose monitoring (CGM) technology (such as Abbott Freestyle Libre 2, previously referred to as Flash Glucose Monitoring) offers real-time glucose monitoring that is convenient and easy to use compared to self-monitoring of blood glucose (SMBG). However, this technology’s use is neither widespread nor subsidised for Aboriginal and Torres Strait Islander peoples with type 2 diabetes. Building on existing collaborations with a national network of Aboriginal and Torres Strait Islander communities, this randomised controlled trial aims to assess the effect of CGM compared to SMBG on (i) haemoglobin A1c (HbA1c), (ii) achieving blood glucose targets, (iii) reducing hypoglycaemic episodes and (iv) cost-effective healthcare in an Aboriginal and Torres Strait Islander people health setting. Methods: This is a non-masked, parallel-group, two-arm, individually randomised, controlled trial (ACTRN12621000753853). Aboriginal and Torres Strait Islander adults with type 2 diabetes on injectable therapy and HbA1c ≥ 7.5% (n = 350) will be randomised (1:1) to CGM or SMBG for 6 months. The primary outcome is change in HbA1c level from baseline to 6 months. Secondary outcomes include (i) CGM-derived metrics, (ii) frequency of hypoglycaemic episodes, (iii) health-related quality of life and (iv) incremental cost per quality-adjusted life year gained associated with the CGM compared to SMBG. Clinical trial sites include Aboriginal Community Controlled Organisations, Aboriginal Medical Services, primary care centres and tertiary hospitals across urban, rural, regional and remote Australia. Discussion: The trial will assess the effect of CGM compared to SMBG on HbA1c for Aboriginal and Torres Strait Islander people with type 2 diabetes in Australia. This trial could have long-term benefits in improving diabetes management and providing evidence for funding of CGM in this population. Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12621000753853. Registered on 15th June 2021. |
| first_indexed | 2024-09-25T04:19:43Z |
| format | Journal article |
| id | oxford-uuid:f75a8174-76cf-48a2-b92b-d0307aea4a66 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:19:43Z |
| publishDate | 2024 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:f75a8174-76cf-48a2-b92b-d0307aea4a662024-07-29T19:33:51ZCan flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f75a8174-76cf-48a2-b92b-d0307aea4a66EnglishJisc Publications RouterBioMed Central2024Hachem, MHearn, TKelly, REer, AMoore, BSommerville, CAtkinson-Briggs, STwigg, SFreund, MO’Neal, DStory, DBrown, AMcLean, ASinha, AFurler, JO’Brien, RTran Duy, AClarke, PBraat, SKoye, DNEades, SBurchill, LEkinci, EBackground: Aboriginal and Torres Strait Islander peoples are disproportionately impacted by type 2 diabetes. Continuous glucose monitoring (CGM) technology (such as Abbott Freestyle Libre 2, previously referred to as Flash Glucose Monitoring) offers real-time glucose monitoring that is convenient and easy to use compared to self-monitoring of blood glucose (SMBG). However, this technology’s use is neither widespread nor subsidised for Aboriginal and Torres Strait Islander peoples with type 2 diabetes. Building on existing collaborations with a national network of Aboriginal and Torres Strait Islander communities, this randomised controlled trial aims to assess the effect of CGM compared to SMBG on (i) haemoglobin A1c (HbA1c), (ii) achieving blood glucose targets, (iii) reducing hypoglycaemic episodes and (iv) cost-effective healthcare in an Aboriginal and Torres Strait Islander people health setting. Methods: This is a non-masked, parallel-group, two-arm, individually randomised, controlled trial (ACTRN12621000753853). Aboriginal and Torres Strait Islander adults with type 2 diabetes on injectable therapy and HbA1c ≥ 7.5% (n = 350) will be randomised (1:1) to CGM or SMBG for 6 months. The primary outcome is change in HbA1c level from baseline to 6 months. Secondary outcomes include (i) CGM-derived metrics, (ii) frequency of hypoglycaemic episodes, (iii) health-related quality of life and (iv) incremental cost per quality-adjusted life year gained associated with the CGM compared to SMBG. Clinical trial sites include Aboriginal Community Controlled Organisations, Aboriginal Medical Services, primary care centres and tertiary hospitals across urban, rural, regional and remote Australia. Discussion: The trial will assess the effect of CGM compared to SMBG on HbA1c for Aboriginal and Torres Strait Islander people with type 2 diabetes in Australia. This trial could have long-term benefits in improving diabetes management and providing evidence for funding of CGM in this population. Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12621000753853. Registered on 15th June 2021. |
| spellingShingle | Hachem, M Hearn, T Kelly, R Eer, A Moore, B Sommerville, C Atkinson-Briggs, S Twigg, S Freund, M O’Neal, D Story, D Brown, A McLean, A Sinha, A Furler, J O’Brien, R Tran Duy, A Clarke, P Braat, S Koye, DN Eades, S Burchill, L Ekinci, E Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial |
| title | Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial |
| title_full | Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial |
| title_fullStr | Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial |
| title_full_unstemmed | Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial |
| title_short | Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with type 2 diabetes? A protocol for a randomised controlled trial |
| title_sort | can flash glucose monitoring improve glucose management for aboriginal and torres strait islander peoples with type 2 diabetes a protocol for a randomised controlled trial |
| work_keys_str_mv | AT hachemm canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT hearnt canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT kellyr canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT eera canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT mooreb canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT sommervillec canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT atkinsonbriggss canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT twiggs canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT freundm canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT oneald canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT storyd canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT browna canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT mcleana canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT sinhaa canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT furlerj canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT obrienr canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT tranduya canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT clarkep canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT braats canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT koyedn canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT eadess canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT burchilll canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial AT ekincie canflashglucosemonitoringimproveglucosemanagementforaboriginalandtorresstraitislanderpeopleswithtype2diabetesaprotocolforarandomisedcontrolledtrial |